Ishida Nobuhiro, Kawakita Masao
Department of Biochemical Cell Research, Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku, 113-8613, Tokyo, Japan.
Pflugers Arch. 2004 Feb;447(5):768-75. doi: 10.1007/s00424-003-1093-0. Epub 2003 May 21.
The solute carrier family SLC35 consists of at least 17 molecular species in humans. The family members so far characterized encode nucleotide sugar transporters localizing at the Golgi apparatus and/or the endoplasmic reticulum (ER). These transporters transport nucleotide sugars pooled in the cytosol into the lumen of these organelles, where most glycoconjugate synthesis occurs. Pathological analyses and developmental studies of small, multicellular organisms deficient in nucleotide sugar transporters have shown these transporters to be involved in tumour metastasis, cellular immunity, organogenesis and morphogenesis. Leukocyte adhesion deficiency type II (LAD II) or the congenital disorder of glycosylation type IIc (CDG IIc) are the sole human congenital disorders known to date that are caused by a defect of GDP-fucose transport. Along with LAD II, the possible involvement of nucleotide sugar transporters in disorders of connective tissues and muscles is also discussed.
溶质载体家族SLC35在人类中至少由17种分子组成。迄今为止已鉴定的家族成员编码定位于高尔基体和/或内质网(ER)的核苷酸糖转运蛋白。这些转运蛋白将聚集在细胞质中的核苷酸糖转运到这些细胞器的腔中,大多数糖缀合物的合成在此处发生。对缺乏核苷酸糖转运蛋白的小型多细胞生物体的病理分析和发育研究表明,这些转运蛋白参与肿瘤转移、细胞免疫、器官发生和形态发生。II型白细胞黏附缺陷症(LAD II)或IIc型先天性糖基化障碍(CDG IIc)是迄今为止已知的仅由GDP-岩藻糖转运缺陷引起的人类先天性疾病。除LAD II外,还讨论了核苷酸糖转运蛋白可能参与结缔组织和肌肉疾病的情况。